FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer - European Medical Journal

Continue

FDA Approves IMFINZI Plus Carboplatin and Paclitaxel for Certain Patients With Endometrial Cancer

Oncology

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.